Company intelligence / Profile preview
Ona Therapeutics
Barcelona, Catalonia, Spainona-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Ona Therapeutics is advancing a pipeline of first-in-class antibody-drug conjugates and monoclonal antibodies targeting advanced solid tumors. Lead program ONA-255 is in IND-enabling studies for breast and other solid tumors, with clinical trials expected to begin by the end of 2025. Additional programs include ONA-389 ADC for prevalent solid tumors and ONA-036 mAb targeting CD36. No clinical results have been reported as all programs are preclinical or IND-enabling.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateMonoclonal antibodyBiologic
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Biocytogen Pharmaceuticals
Beyond the preview
Go deeper on Ona Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ona Therapeutics.